Prognostic Value of the KRAS G12V Mutation in 841 Surgically Resected Caucasian Lung Adenocarcinoma Cases

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Sep 16

PMID 26372703

Citations 32

Authors

Stephane Renaud

Pierre-Emmanuel Falcoz

Mickael Schaeffer

Dominique Guenot

Benoit Romain

Anne Olland

Jeremie Reeb

Nicola Santelmo

Marie-Pierre Chenard

Michele Legrain

Anne-Claire Voegeli

Michele Beau-Faller

Gilbert Massard

Affiliations

Soon will be listed here.

Abstract

Background: Identifying patients who will experience lung cancer recurrence after surgery remains a challenge. We aimed to evaluate whether mutant forms of epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) (mEGFR and mKRAS) are useful biomarkers in resected non-small cell lung cancer (NSCLC).

Methods: We retrospectively reviewed data from 841 patients who underwent surgery and molecular testing for NSCLC between 2007 and 2012.

Results: mEGFR was observed in 103 patients (12.2%), and mKRAS in 265 (31.5%). The median overall survival (OS) and time to recurrence (TTR) were significantly lower for mKRAS (OS: 43 months; TTR: 19 months) compared with mEGFR (OS: 67 months; TTR: 24 months) and wild-type patients (OS: 55 months; disease-free survival (DFS): 24 months). Patients with KRAS G12V exhibited worse OS and TTR compared with the entire cohort (OS: KRAS G12V: 26 months vs

Cohort: 24 months). These results were confirmed using multivariate analyses (non-G12V status, hazard ratio (HR): 0.43 (confidence interval: 0.28-0.65), P<0.0001 for OS; HR: 0.67 (0.48-0.92), P=0.01 for TTR). Risk of recurrence was significantly lower for non-KRAS G12V (HR: 0.01, (0.001-0.08), P<0.0001).

Conclusions: mKRAS and mEGFR may predict survival and recurrence in early stages of NSCLC. Patients with KRAS G12V exhibited worse OS and higher recurrence incidences.

Citing Articles

Distribution of and Mutations in Patients with Surgically Resected Non-Small Cell Lung Cancer from Southern Italy: Real-Life Data from a Single Institution and Literature Review.

Piazzolla M, Parente P, Centra F, Fabrizio F, Delcuratolo M, Centonza A Cancers (Basel). 2025; 17(5).

PMID: 40075579 PMC: 11899559. DOI: 10.3390/cancers17050730.

Bone marrow adipocytes and lung cancer bone metastasis: unraveling the role of adipokines in the tumor microenvironment.

Li J, Wu J, Xie Y, Yu X Front Oncol. 2024; 14:1360471.

PMID: 38571500 PMC: 10987778. DOI: 10.3389/fonc.2024.1360471.

Advances in cancer DNA methylation analysis with methPLIER: use of non-negative matrix factorization and knowledge-based constraints to enhance biological interpretability.

Takasawa K, Asada K, Kaneko S, Shiraishi K, Machino H, Takahashi S Exp Mol Med. 2024; 56(3):646-655.

PMID: 38433247 PMC: 10985003. DOI: 10.1038/s12276-024-01173-7.

Prognostic Role of Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Wankhede D, Bontoux C, Grover S, Hofman P Diagnostics (Basel). 2023; 13(19).

PMID: 37835787 PMC: 10572143. DOI: 10.3390/diagnostics13193043.

Genomic features and its potential implication in bone oligometastatic NSCLC.

Liao R, Yi G, Shen L, Zhang X, Xu Z, Peng Y BMC Pulm Med. 2023; 23(1):59.

PMID: 36755257 PMC: 9906959. DOI: 10.1186/s12890-023-02354-2.

References

Janjigian Y, Park B, Zakowski M, Ladanyi M, Pao W, DAngelo S . Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 2010; 6(3):569-75. PMC: 3778680. DOI: 10.1097/JTO.0b013e318202bffe. View

Izar B, Zhou H, Heist R, Azzoli C, Muzikansky A, Scribner E . The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol. 2014; 9(9):1363-9. DOI: 10.1097/JTO.0000000000000266. View

Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N . A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009; 15(6):489-500. PMC: 2743093. DOI: 10.1016/j.ccr.2009.03.022. View

Romain B, Hachet-Haas M, Rohr S, Brigand C, Galzi J, Gaub M . Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol Cancer. 2014; 13:58. PMC: 3975457. DOI: 10.1186/1476-4598-13-58. View

Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F . A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute.... J Mol Diagn. 2013; 16(1):45-55. DOI: 10.1016/j.jmoldx.2013.07.009. View

Ihle N, Byers L, Kim E, Saintigny P, Lee J, Blumenschein G . Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012; 104(3):228-39. PMC: 3274509. DOI: 10.1093/jnci/djr523. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Thomas P, Dahan M, Riquet M, Massart G, Falcoz P, Brouchet L . [Practical issues in the surgical treatment of non-small cell lung cancer. Recommendations from the French Society of Thoracic and Cardiovascular Surgery]. Rev Mal Respir. 2008; 25(8):1031-6. DOI: 10.1016/s0761-8425(08)74419-x. View

Zhang Z, Wang T, Zhang J, Cai X, Pan C, Long Y . Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis. PLoS One. 2014; 9(8):e106053. PMC: 4146589. DOI: 10.1371/journal.pone.0106053. View

10.

Goss G, OCallaghan C, Lorimer I, Tsao M, Masters G, Jett J . Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013; 31(27):3320-6. PMC: 3770864. DOI: 10.1200/JCO.2013.51.1816. View

11.

Nadal E, Chen G, Prensner J, Shiratsuchi H, Sam C, Zhao L . KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol. 2014; 9(10):1513-22. DOI: 10.1097/JTO.0000000000000305. View

12.

Garassino M, Marabese M, Rusconi P, Rulli E, Martelli O, Farina G . Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2010; 22(1):235-237. DOI: 10.1093/annonc/mdq680. View

13.

Zhai H, Zhong W, Yang X, Wu Y . Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. Transl Lung Cancer Res. 2015; 4(1):82-93. PMC: 4367710. DOI: 10.3978/j.issn.2218-6751.2014.11.08. View

14.

DAngelo S, Janjigian Y, Ahye N, Riely G, Chaft J, Sima C . Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012; 7(12):1815-1822. DOI: 10.1097/JTO.0b013e31826bb7b2. View

15.

Uramoto H, Tanaka F . Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2015; 3(4):242-9. PMC: 4367696. DOI: 10.3978/j.issn.2218-6751.2013.12.05. View

16.

Meng D, Yuan M, Li X, Chen L, Yang J, Zhao X . Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer. 2013; 81(1):1-10. DOI: 10.1016/j.lungcan.2013.03.019. View

17.

Alamo P, Gallardo A, Di Nicolantonio F, Pavon M, Casanova I, Trias M . Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB J. 2014; 29(2):464-76. DOI: 10.1096/fj.14-262303. View

18.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

19.

Beau-Faller M, LEGRAIN M, Voegeli A, Guerin E, Lavaux T, Ruppert A . Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer. 2009; 100(6):985-92. PMC: 2661785. DOI: 10.1038/sj.bjc.6604925. View

20.

Marks J, Broderick S, Zhou Q, Chitale D, Li A, Zakowski M . Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008; 3(2):111-6. DOI: 10.1097/JTO.0b013e318160c607. View